# Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

> **NCT07197671** · PHASE1 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** 90Y-NM600

## Key facts

- **NCT ID:** NCT07197671
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07197671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07197671, "Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07197671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*